Compare SciBase Holding AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 338 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-3.02
-1,475.83%
50.78
Revenue and Profits:
Net Sales:
14 Million
(Quarterly Results - Mar 2026)
Net Profit:
-24 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
25.14%
0%
25.14%
6 Months
25.83%
0%
25.83%
1 Year
46.13%
0%
46.13%
2 Years
-63.7%
0%
-63.7%
3 Years
-87.91%
0%
-87.91%
4 Years
-91.62%
0%
-91.62%
5 Years
-79.26%
0%
-79.26%
SciBase Holding AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
31.59%
EBIT Growth (5y)
-184.13%
EBIT to Interest (avg)
-43.51
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.80
Sales to Capital Employed (avg)
1.10
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.67
EV to EBIT
-2.81
EV to EBITDA
-2.92
EV to Capital Employed
26.59
EV to Sales
6.34
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-946.10%
ROE (Latest)
-269.96%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
14.30
12.50
14.40%
Operating Profit (PBDIT) excl Other Income
-24.20
-25.00
3.20%
Interest
0.30
0.10
200.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-24.50
-25.30
3.16%
Operating Profit Margin (Excl OI)
-1,693.30%
-2,116.30%
42.30%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 14.40% vs 21.36% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 3.16% vs -34.57% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
40.50
29.70
36.36%
Operating Profit (PBDIT) excl Other Income
-81.50
-63.70
-27.94%
Interest
0.40
0.30
33.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-87.10
-65.60
-32.77%
Operating Profit Margin (Excl OI)
-2,105.30%
-2,254.30%
14.90%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 36.36% vs 28.02% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -32.77% vs -17.99% in Dec 2024
About SciBase Holding AB 
SciBase Holding AB
Pharmaceuticals & Biotechnology
SciBase Holding AB is a Sweden-based company engaged in the medical equipment industry. The Company specializes in the manufacture of point of care device, called Nevisense, which is aimed to detect of malignant melanoma. Nevisense analyze suspicious lesions by using Electrical Impedance Spectroscopy (EIS) which is applied as an electrical signal to the skin. The diagnostic product is sold in Nordic countries, Belgium, Germany, Great Britain and Australia.






